Edgewise Therapeutics, Inc.
EWTX
Jodie situation report
Edgewise Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 10 directly disclosed connections are confirming.
- EWTX's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if EWTX's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind EWTX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
CYTKCytokinetics, IncorporatedcompetitorMay 7, 2026 ▾
“In the field of emerging treatments for HCM, competitors include Bristol-Myers Squibb (BMS), Cytokinetics, Imbria Pharmaceuticals, Lexicon Pharmaceuticals, and Celltrion, and Braveheart Bio.”
CYTKCytokinetics, IncorporatedsupplierFeb 26, 2026 ▾
“The effects of EDG-7500 on cardiac function overlap with some of the desirable attributes of the cardiac myosin inhibitors (CMIs) such as BMS’s CAMZYOS® (mavacamten) and Cytokinetics’ MYQORZO (aficamten).”
Depended on by
CYTKCytokinetics, IncorporatedcompetitorFeb 26, 2026 ▾
“In addition to Camzyos®, Edgewise Therapeutics, Lexicon, Tenaya and Braveheart Bio (Hengrui) are conducting clinical trials and could commercialize a drug that would compete with MYQORZO if successful.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
EWTX is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.